JAGSNPHARM Jagsonpal Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
Jagsonpal Pharma reported a strong recovery in Q4 FY26, with revenue growing 10% YoY to INR64 crores and PAT increasing 31% YoY to INR9 crores. For the full year, revenue grew 7% to INR287 crores, and net profit grew 19% to INR45 crores. The company announced a INR40 crores share buyback and a 200% dividend, reflecting confidence in its business model and commitment to shareholder value, while targeting 1.5x IPM growth for FY27 and beyond.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 8.5%, net profit up 28.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 59 | 76 | 74 −1% | 73 −1% | 64 +8% |
| EBITDA | 16 | 16 | 9 | 14 | 16 +0% | 16 +0% | 11 +22% |
| Net profit | 11 | 32 | 7 | 11 | 13 +18% | 11 −66% | 9 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
